|
|
Post by tw12 on Apr 5, 2019 9:26:04 GMT -5
Imagine what each of us, in all our ProBoard diversity, would say at the next meeting if we were on the board...
Here's what I'd offer:
"Let's make sure, with all our potential products and alliances, that we investigate the entire worldwide market for Afrezza now. Not just Brazil, India, Canada and Mexico, but China, Indonesia, Malaysia, Nigeria, Egypt, South Africa, Australia. Let's discover the current challenges, identify potential partners now. Let's get ahead of the long time frame it takes for government approval. It's such huge market potential, 400 million diabetics and growing rapidly. And as we establish traction overseas, it will strengthen not only the Afrezza story but, by reinforcing the ease and efficacy of Technosphere itself, will aid the entire pipeline we're working on..."
|
|
|
|
Post by uvula on Apr 5, 2019 10:31:29 GMT -5
You do sound like a CEO. "Investigate the entire worldwide market" is a weasel phrase that doesn't really commit the company to doing anything concrete.
|
|
|
|
Post by traderdennis on Apr 5, 2019 11:21:56 GMT -5
How about doing one market well, before spreading the company too thin. If you can't make it in the US, the company is not going to be profitable.
|
|
|
|
Post by tw12 on Apr 5, 2019 11:26:36 GMT -5
Let's avoid kneejerk negativism here. The idea is to offer thoughtful strategy about what you would contribute as a board member....
|
|
|
|
Post by buyitonsale on Apr 5, 2019 12:04:57 GMT -5
We need to focus on Medicare and Medicaid insurance coverage in this country first.
Target primary care care physicians instead of endocrinologists as they control a lot more population within managed care. Let outcomes and quality of care measure scores convince payers to move up Afrezza in their formularies.
Canada is a huge single payer country next door, what are we waiting for ?
|
|
|
|
Post by agedhippie on Apr 5, 2019 12:31:37 GMT -5
Simple question. What are our metrics?
Right now there is no eps target, no revenue target, nothing. The only target seems to be to remain in business and that's pretty much a given.
If we can publish and hit metrics then institutions will have the confidence to invest.
|
|
|
|
Post by mytakeonit on Apr 5, 2019 13:54:15 GMT -5
Our metrics is "Where no Mannkind has gone before ... to the far reaches of the universe"
|
|
|
|
Post by ktim on Apr 5, 2019 15:51:26 GMT -5
You do sound like a CEO. "Investigate the entire worldwide market" is a weasel phrase that doesn't really commit the company to doing anything concrete. After investigation comes "targeting". That's when the excitement of concretely coloring it blue on the world map happens. |
|
|
|
Post by bigchungus91354 on Apr 5, 2019 15:55:02 GMT -5
You do sound like a CEO. "Investigate the entire worldwide market" is a weasel phrase that doesn't really commit the company to doing anything concrete. After investigation comes "targeting". That's when the excitement of concretely coloring it blue on the world map happens. MNKD could just "target" every country in the world, that doesn't cost anything. SpaceX is targeting trips to the moon, maybe MNKD could target Afrezza on the moon? |
|
|
|
Post by ktim on Apr 5, 2019 16:07:51 GMT -5
After investigation comes "targeting". That's when the excitement of concretely coloring it blue on the world map happens. MNKD could just "target" every country in the world, that doesn't cost anything. SpaceX is targeting trips to the moon, maybe MNKD could target Afrezza on the moon? Silly rabbit, they only have one blue crayon. They can't waste it coloring in every country. And Trix are still for kids. |
|
|
|
Post by boca1girl on Apr 5, 2019 18:26:12 GMT -5
Simple question. What are our metrics? Right now there is no eps target, no revenue target, nothing. The only target seems to be to remain in business and that's pretty much a given. If we can publish and hit metrics then institutions will have the confidence to invest. We did have a revenue target in 2018 and that didn’t work out too well. |
|
|
|
Post by agedhippie on Apr 5, 2019 19:07:01 GMT -5
Simple question. What are our metrics? Right now there is no eps target, no revenue target, nothing. The only target seems to be to remain in business and that's pretty much a given. If we can publish and hit metrics then institutions will have the confidence to invest. We did have a revenue target in 2018 and that didn’t work out too well. True, but the good news is that despite missing the one key metric they gave by a country mile everyone still got their bonuses. If management (and ultimately the CEO) cannot hit their own revenue figure then something is badly wrong with their strategy and assumptions. It doesn't build confidence! |
|
|
|
Post by prcgorman2 on Apr 5, 2019 19:24:05 GMT -5
We know they missed their target but we don’t know the details why. Easy to blame management, but given all of the horse—— that’s happened to this company, I’m not ready to lay it at their feet. I don’t like targets for Afrezza at this stage. I keep coming back to the poor SOB who goes to the PCP or endo office with their single product offering. It’s got to be an awful job. It will be a very good thing to focus the shoe leather on being diabetes educators. I almost think we should only be hiring PWD sales folks out of college with biology or pharma degrees.
Anwyay, to tw12’s point, an important role of a CEO is to set vision and it’s the board’s job to help ensure the vision aligns with the interest of the company and it’s shareholders.
I think researching worldwide marketability is not at all silly and is visionary and can be done with a modest investment.
You could hire an intern or two just to generate reports of basics such as PWDs, insurance programs, whether a country is known for taking FDA approval as “good enough” or what additional requirements they may have, et cetera, and use the information to plot a strategy for development. If nothing else it makes you more informed and a better negotiator when looking for the next rest-of-world partner which they’ve said they’re interested in.
|
|
|
|
Post by sportsrancho on Apr 5, 2019 20:33:01 GMT -5
I can’t imagine a harder job than the reps have. And I certainly don’t blame Mike for being optimistic about his guidance.
But the model doesn’t work, they are strangled by the label, they can’t educate the doctors about the correct way to dose or to use Afrezza to get the optimum results. And 10 minutes with your Endo every two months doesn’t cut it. That’s why the reps try to find the patients Afrezza buddies. The more the “Afrezza village” builds the better it will get.
But as sayhey says clinics are the best protocol. IMO
Also I wouldn’t mind seeing them co/partnering with SENS, ( CGM ) And have twice as many reps. Laura could even be the face for both:-)
|
|
|
|
Post by mango on Apr 5, 2019 20:42:07 GMT -5
Co-promote with United.
|
|
